vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and Rumble Inc. (RUM). Click either name above to swap in a different company.
Rumble Inc. is the larger business by last-quarter revenue ($27.1M vs $23.0M, roughly 1.2× Intellia Therapeutics, Inc.). Rumble Inc. runs the higher net margin — -120.8% vs -416.2%, a 295.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -10.5%). Rumble Inc. produced more free cash flow last quarter ($-31.7M vs $-69.4M). Over the past eight quarters, Rumble Inc.'s revenue compounded faster (15.2% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Rumble is a Canadian-American online video platform, web hosting, and cloud services business headquartered in Toronto, Canada, with its U.S. headquarters in Longboat Key, Florida. It was founded in 2013 by Chris Pavlovski, a Canadian technology entrepreneur. Rumble's cloud services business hosts Truth Social, and the video platform is popular among American conservative and far-right users. Rumble has been described as "alt-tech".
NTLA vs RUM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $27.1M |
| Net Profit | $-95.8M | $-32.7M |
| Gross Margin | — | 5.5% |
| Operating Margin | -428.9% | -131.1% |
| Net Margin | -416.2% | -120.8% |
| Revenue YoY | 78.8% | -10.5% |
| Net Profit YoY | 25.7% | 86.2% |
| EPS (diluted) | $-0.81 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $27.1M | ||
| Q3 25 | $13.8M | $24.8M | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $16.6M | $23.7M | ||
| Q4 24 | $12.9M | $30.2M | ||
| Q3 24 | $9.1M | $25.1M | ||
| Q2 24 | $7.0M | $22.5M | ||
| Q1 24 | $28.9M | $17.7M |
| Q4 25 | $-95.8M | $-32.7M | ||
| Q3 25 | $-101.3M | $-16.3M | ||
| Q2 25 | $-101.3M | — | ||
| Q1 25 | $-114.3M | $-2.7M | ||
| Q4 24 | $-128.9M | $-236.8M | ||
| Q3 24 | $-135.7M | $-31.5M | ||
| Q2 24 | $-147.0M | $-26.8M | ||
| Q1 24 | $-107.4M | $-43.3M |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
| Q4 25 | -428.9% | -131.1% | ||
| Q3 25 | -808.9% | -113.6% | ||
| Q2 25 | -772.2% | — | ||
| Q1 25 | -726.6% | -153.5% | ||
| Q4 24 | -1059.9% | -80.1% | ||
| Q3 24 | -1589.0% | -131.0% | ||
| Q2 24 | -1998.6% | -172.7% | ||
| Q1 24 | -394.0% | -197.4% |
| Q4 25 | -416.2% | -120.8% | ||
| Q3 25 | -735.2% | -65.7% | ||
| Q2 25 | -710.8% | — | ||
| Q1 25 | -687.6% | -11.2% | ||
| Q4 24 | -1001.2% | -783.2% | ||
| Q3 24 | -1489.5% | -125.9% | ||
| Q2 24 | -2112.6% | -119.2% | ||
| Q1 24 | -371.3% | -244.1% |
| Q4 25 | $-0.81 | $-0.13 | ||
| Q3 25 | $-0.92 | $-0.06 | ||
| Q2 25 | $-0.98 | — | ||
| Q1 25 | $-1.10 | $-0.01 | ||
| Q4 24 | $-1.27 | $-1.17 | ||
| Q3 24 | $-1.34 | $-0.15 | ||
| Q2 24 | $-1.52 | $-0.13 | ||
| Q1 24 | $-1.12 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $237.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $274.8M |
| Total Assets | $842.1M | $336.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $237.9M | ||
| Q3 25 | $511.0M | $269.8M | ||
| Q2 25 | $459.7M | — | ||
| Q1 25 | $503.7M | $301.3M | ||
| Q4 24 | $601.5M | $114.0M | ||
| Q3 24 | $658.1M | $132.0M | ||
| Q2 24 | $691.1M | $154.2M | ||
| Q1 24 | $791.3M | $183.8M |
| Q4 25 | $671.4M | $274.8M | ||
| Q3 25 | $748.4M | $302.2M | ||
| Q2 25 | $715.3M | — | ||
| Q1 25 | $779.9M | $339.6M | ||
| Q4 24 | $872.0M | $-63.1M | ||
| Q3 24 | $962.6M | $166.1M | ||
| Q2 24 | $971.1M | $192.7M | ||
| Q1 24 | $1.0B | $210.7M |
| Q4 25 | $842.1M | $336.8M | ||
| Q3 25 | $925.3M | $367.2M | ||
| Q2 25 | $898.9M | — | ||
| Q1 25 | $986.2M | $391.1M | ||
| Q4 24 | $1.2B | $195.3M | ||
| Q3 24 | $1.2B | $217.2M | ||
| Q2 24 | $1.2B | $243.2M | ||
| Q1 24 | $1.3B | $263.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $-29.4M |
| Free Cash FlowOCF − Capex | $-69.4M | $-31.7M |
| FCF MarginFCF / Revenue | -301.6% | -117.2% |
| Capex IntensityCapex / Revenue | 0.5% | 8.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $-70.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $-29.4M | ||
| Q3 25 | $-76.9M | $-10.6M | ||
| Q2 25 | $-99.6M | — | ||
| Q1 25 | $-148.9M | $-14.5M | ||
| Q4 24 | $-85.2M | $-12.4M | ||
| Q3 24 | $-84.8M | $-19.1M | ||
| Q2 24 | $-58.2M | $-21.7M | ||
| Q1 24 | $-120.7M | $-33.9M |
| Q4 25 | $-69.4M | $-31.7M | ||
| Q3 25 | $-76.9M | $-12.0M | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-149.7M | $-14.6M | ||
| Q4 24 | $-86.2M | $-12.4M | ||
| Q3 24 | $-86.1M | $-19.9M | ||
| Q2 24 | $-59.2M | $-23.1M | ||
| Q1 24 | $-123.2M | $-34.3M |
| Q4 25 | -301.6% | -117.2% | ||
| Q3 25 | -558.2% | -48.6% | ||
| Q2 25 | -701.0% | — | ||
| Q1 25 | -900.1% | -61.7% | ||
| Q4 24 | -669.4% | -40.9% | ||
| Q3 24 | -945.2% | -79.5% | ||
| Q2 24 | -850.9% | -102.8% | ||
| Q1 24 | -425.7% | -193.3% |
| Q4 25 | 0.5% | 8.5% | ||
| Q3 25 | 0.2% | 5.7% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.4% | 0.6% | ||
| Q4 24 | 7.6% | 0.1% | ||
| Q3 24 | 14.0% | 3.4% | ||
| Q2 24 | 14.5% | 6.1% | ||
| Q1 24 | 8.7% | 2.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
